Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abdominal Paraaortic Lymphadenopathy With Progressive Transformation of Germinal Centers.

Pediatrics international : official journal of the Japan Pediatric Society·2026
Same author

Adult T-cell leukaemia/lymphoma with different histological features in a single lymph node.

Journal of clinical and experimental hematopathology : JCEH·2026
Same author

Fibrin-associated large B-cell lymphoma arising in benign gynecologic tumors: insights into disease spectrum expansion and pathophysiology.

Virchows Archiv : an international journal of pathology·2026
Same author

[Successful treatment with brentuximab vedotin for MYC positive syncytial variant nodular sclerosis Hodgkin lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same author

A case of primary testicular adult T-cell leukemia/lymphoma (ATLL): ATLL of immune privileged site.

Journal of clinical and experimental hematopathology : JCEH·2025
Same author

Orally available decitabine prodrug OR-2100 induces mitotic perturbation for the treatment of double-hit lymphoma.

Blood neoplasia·2025

Related Experiment Video

Updated: Feb 28, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.3K

Papillary thyroid carcinoma expressing CD20.

Yuya Sasaki1, Masao Seto1, Hiroaki Miyoshi1

  • 1Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan.

Pathology International
|June 16, 2017
PubMed
Summary
This summary is machine-generated.

Papillary thyroid carcinoma (PTC) can express CD20, a protein targeted in lymphoma therapy. This study found CD20 in 23% of PTC cases, suggesting a potential new treatment approach for CD20-positive thyroid cancer.

Keywords:
CD20papillary thyroid carcinomathyroid cancer

More Related Videos

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

1.1K
Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
04:01

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

1.6K

Related Experiment Videos

Last Updated: Feb 28, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.3K
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

1.1K
Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
04:01

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

1.6K

Area of Science:

  • Oncology
  • Immunology
  • Pathology

Background:

  • Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer.
  • CD20 is a well-established therapeutic target in B-cell lymphomas.
  • The expression of CD20 in PTC has not been previously reported.

Purpose of the Study:

  • To investigate the expression of CD20 in metastatic papillary thyroid carcinoma.
  • To determine the prevalence of CD20 expression in a cohort of PTC cases.
  • To explore the potential therapeutic implications of CD20 expression in PTC.

Main Methods:

  • Immunohistochemistry (IHC) using L26 clone and N-terminus recognizing antibody on metastatic PTC biopsy.
  • Validation with fluorescent double staining for CD20 and TTF-1.
  • Screening of 21 additional PTC cases for CD20 expression.

Main Results:

  • CD20 expression was identified in a case of metastatic PTC and its primary tumor.
  • CD20 positivity was confirmed by a second antibody and fluorescent staining.
  • Five out of 22 (23%) PTC cases evaluated were positive for CD20.

Conclusions:

  • Papillary thyroid carcinoma can express CD20, a target for B-cell lymphoma therapy.
  • The findings suggest that anti-CD20 therapy may be a viable treatment option for a subset of CD20-positive PTC patients.
  • This study provides the first evidence of CD20 expression in PTC, opening avenues for novel therapeutic strategies.